Allison Jeynes-Ellis MD

After qualifying as an MD, Dr Allison Jeynes spent time practicing medicine and specialising in oncology working at various NHS institutions, including The Royal Marsden, London before moving into the life sciences industry predominantly within research and development. Now with close to 30 years experience she has led the strategic direction of Avillion LLP as its CEO since 2014 and has a proven track record of delivering results.

Avillion LLP is a boutique Life Sciences investment firm who fund and operationalise clinical trials for other companies. Avillion is funded by Blackstone Lifesciences and Abingworth, investing in post POC Co-Development deals from $50m to $600m taking all the clinical & regulatory risk around approval.

Prior to Avillion, Allison held a range of senior roles, including Medical Director for Wyeth for 6 years and International Project Team Leader for many compounds in development, leading global Phase III programmes through to successful US and EU filings.

Allison sits on the Board of Directors of Agenus, Anaveon, Siolta and is the Non-Executive Chair of OxSonics. Allison is also a Senior Advisor to Blackstone Life Sciences and a Special Advisor to Abingworth.